Literature DB >> 12783104

Voriconazole: A second-generation triazole.

P. H. Chandrasekar1, E. Manavathu.   

Abstract

Voriconazole, a derivative of fluconazole, is an antifungal triazole with expanded spectrum of activity against a variety of yeasts and filamentous fungi. It exhibits fungicidal activity against Aspergillus species. Preliminary data from animal models and clinical trials show promise in the treatment of candidiasis and aspergillosis. Of concern is the development of resistance to voriconazole and cross-resistance with other azoles. Voriconazole is a welcome addition to our limited armamentarium against potentially fatal fungal infections. (c) 2001 Prous Science. All rights reserved.

Entities:  

Year:  2001        PMID： 12783104     DOI： 10.1358/dot.2001.37.2.614849

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN： 1699-3993            Impact factor:   2.245


  26 in total

1.  No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Lynn Purkins; Nolan Wood; Parviz Ghahramani; Diane Kleinermans; Gary Layton; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

2.  [Painless cutaneous nodes in a 61-year old male stem cell transplantation patient].

Authors:  J Brasch
Journal:  Hautarzt       Date:  2004-12       Impact factor: 0.751

3.  The pharmacokinetics of voriconazole.

Authors:  Atholl Johnston
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

4.  Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.

Authors:  Ronald N Jones; Mariana Castanheira; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  In vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.

Authors:  Ana Paula Miranda Duarte; Fernando Carlos Pagnocca; Noemi Carla Baron; Marcia de Souza Carvalho Melhem; Gislene Aparecida Palmeira; Dejanira de Franceschi de Angelis; Derlene Attili-Angelis
Journal:  Mycopathologia       Date:  2012-11-16       Impact factor: 2.574

8.  Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.

Authors:  Maria José Linares; Guadalupe Charriel; Francisco Solís; Manuel Casal
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

9.  Aqueous humor concentration of voriconazole after topical administration in rabbits.

Authors:  Christian K Vorwerk; F Streit; L Binder; S Tuchen; C Knop; W Behrens-Baumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-20       Impact factor: 3.117

10.  Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.

Authors:  Samantha Abel; Richard Allan; Kuan Gandelman; Konrad Tomaszewski; David J Webb; Nolan D Wood
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.